{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:45:37Z","timestamp":1782535537621,"version":"3.54.5"},"reference-count":13,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Methocarbamol is a central nervous system depressant with antispasmodic properties used as a skeletal muscle relaxant as part of a multimodal analgesia regimen in critically ill patients. Intravenous (IV) methocarbamol contains polyethylene glycol (PEG) 300 and propylene glycol (PG) which have been associated with acute kidney injury (AKI). To mitigate AKI risk, IV methocarbamol is limited to 72 consecutive hours, followed by a 48-hour drug-free interval (DFI).\n                    <jats:bold>Objective:<\/jats:bold>\n                    To characterize the incidence of AKI in intensive care unit (ICU) patients receiving IV methocarbamol.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This is a single-center, retrospective evaluation of adult trauma or surgical ICU patients who received at least 3 consecutive doses of IV methocarbamol. The primary outcome was the difference in SCr from day 1 through day 7 after IV methocarbamol initiation.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 68 patients met inclusion criteria. Four patients were classified in the non-DFI group. There was no difference in the median (IQR) SCr (mg\/dL) measured at any time point from day 1 through day 7 after IV methocarbamol initiation in the entire cohort [0.83 (0.71, 1.08) vs 0.74 (0.62, 1.33),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.55]. There was no difference between the median (IQR) SCr (mg\/dL) from day 1 through day 7 in patients that had no DFI [1.04 (0.89, 2.56) vs 1.20 (0.79, 2.92),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.84].\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    No statistically significant change in SCr was observed over time in critically ill patients receiving IV methocarbamol regardless of DFI use.\n                  <\/jats:p>","DOI":"10.1177\/08971900251394101","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:34:37Z","timestamp":1761694477000},"page":"330-334","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Link Between Intravenous Methocarbamol and Acute Kidney Injury"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1320-7134","authenticated-orcid":false,"given":"Matthew","family":"Li","sequence":"first","affiliation":[{"name":"Westchester Medical Center"},{"name":"New York Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Wilson","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Dudley","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"D\u2019agostino","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel","family":"Brennen","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anrew","family":"Villion","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bronstein","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020964796"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13741-019-0114-2"},{"key":"e_1_3_3_4_2","unstructured":"Amneal Pharmaceuticals LLC. Methocarbamol (Robaxin) [package insert]. Published online July 2023. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=090a3d3d-92c3-4c30-a648-436461f81702. Accessed February 4 2025."},{"key":"e_1_3_3_5_2","volume-title":"Goldfrank\u2019s Toxicologic Emergencies, 10e","author":"Nordt SP","year":"2015","unstructured":"Nordt SP, Vivero LE. Pharmaceutical additives. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, eds. Goldfrank\u2019s Toxicologic Emergencies, 10e. McGraw-Hill Education; 2015. Accessed February 4, 2025.https:\/\/accesspharmacy.mhmedical.com\/content.aspx?aid=1108430016"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(97)90577-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01381-2"},{"key":"e_1_3_3_8_2","first-page":"545","volume-title":"Handbook of Pharmaceutical Excipients","author":"Price J","year":"2006","unstructured":"Price J. Polethylene glycol. In: Handbook of Pharmaceutical Excipients. 5th ed. American Pharmacists Association; 2006:545-549.","edition":"5"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.11.015"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502901107"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00026-2016"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2024.2345322"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011203032116"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/faat.1994.1076"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251394101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251394101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251394101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:56:46Z","timestamp":1782532606000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251394101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/08971900251394101"],"URL":"https:\/\/doi.org\/10.1177\/08971900251394101","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}